Hayes H, Nicolini A, Arrowood C, Chvatal S, Wolfson D, Cho H, et al. Novel method for action potential measurements from intact cardiac monolayers with multiwell microelectrode array technology. Sci Rep. 2019;9:11893 pubmed publisher

Clements M, Millar V, Williams A, Kalinka S. Bridging Functional and Structural Cardiotoxicity Assays Using Human Embryonic Stem Cell-Derived Cardiomyocytes for a More Comprehensive Risk Assessment. Toxicol Sci. 2015;148:241-60 pubmed publisher

Lee E, Wu Z, Shon J, Liu K. Danazol Inhibits Cytochrome P450 2J2 Activity in a Substrate-independent Manner. Drug Metab Dispos. 2015;43:1250-3 pubmed publisher

Doherty K, TALBERT D, Trusk P, Moran D, Shell S, Bacus S. Structural and functional screening in human induced-pluripotent stem cell-derived cardiomyocytes accurately identifies cardiotoxicity of multiple drug types. Toxicol Appl Pharmacol. 2015;285:51-60 pubmed publisher

Kim H, Lee W, Lee K, Bae S, Kim M, Joo Y, et al. Efficacy of Helicobacter pylori eradication for the 1st line treatment of immune thrombocytopenia patients with moderate thrombocytopenia. Ann Hematol. 2015;94:739-46 pubmed publisher

Back H, Lee J, Yun H, Kwon K. Development of QTc prolongation model incorporating circadian rhythm using harmonic model. Xenobiotica. 2015;45:420-7 pubmed publisher

Yun J, Kim S. Antihistamines modulate the integrin signaling pathway in h9c2 rat cardiomyocytes: Possible association with cardiotoxicity. Hum Exp Toxicol. 2015;34:796-807 pubmed publisher

Anwar Mohamed A, Barakat K, Bhat R, Noskov S, Tyrrell D, Tuszynski J, et al. A human ether-á-go-go-related (hERG) ion channel atomistic model generated by long supercomputer molecular dynamics simulations and its use in predicting drug cardiotoxicity. Toxicol Lett. 2014;230:382-92 pubmed publisher

Eksterowicz J, Rock D, Rock B, Wienkers L, Foti R. Characterization of the active site properties of CYP4F12. Drug Metab Dispos. 2014;42:1698-707 pubmed publisher

Prado A, Petroianu G, Lorke D, Chambers J. A trivalent approach for determining in vitro toxicology: Examination of oxime K027. J Appl Toxicol. 2015;35:219-27 pubmed publisher

Lee B, Wu Z, Sung S, Lee T, Song K, Lee M, et al. Potential of decursin to inhibit the human cytochrome P450 2J2 isoform. Food Chem Toxicol. 2014;70:94-9 pubmed publisher

Girault A, Privé A, Trinh N, Bardou O, Ferraro P, Joubert P, et al. Identification of KvLQT1 K+ channels as new regulators of non-small cell lung cancer cell proliferation and migration. Int J Oncol. 2014;44:838-48 pubmed publisher

Karapetyan Y, Sferrazza G, Zhou M, Ottenberg G, Spicer T, Chase P, et al. Unique drug screening approach for prion diseases identifies tacrolimus and astemizole as antiprion agents. Proc Natl Acad Sci U S A. 2013;110:7044-9 pubmed publisher

Vlaar T, Cioc R, Mampuys P, Maes B, Orru R, Ruijter E. Sustainable synthesis of diverse privileged heterocycles by palladium-catalyzed aerobic oxidative isocyanide insertion. Angew Chem Int Ed Engl. 2012;51:13058-61 pubmed publisher

Fano S, Caliskan G, Heinemann U. Differential effects of blockade of ERG channels on gamma oscillations and excitability in rat hippocampal slices. Eur J Neurosci. 2012;36:3628-35 pubmed publisher

García Quiroz J, García Becerra R, Barrera D, Santos N, Avila E, Ordaz Rosado D, et al. Astemizole synergizes calcitriol antiproliferative activity by inhibiting CYP24A1 and upregulating VDR: a novel approach for breast cancer therapy. PLoS ONE. 2012;7:e45063 pubmed publisher

Garg V, Sachse F, Sanguinetti M. Tuning of EAG K(+) channel inactivation: molecular determinants of amplification by mutations and a small molecule. J Gen Physiol. 2012;140:307-24 pubmed publisher

Lee C, Jones J, Katayama J, Kaspera R, Jiang Y, Freiwald S, et al. Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity. Drug Metab Dispos. 2012;40:943-51 pubmed publisher

Nomura F, Kaneko T, Hattori A, Yasuda K. On-chip constructive cell-network study (II): on-chip quasi-in vivo cardiac toxicity assay for ventricular tachycardia/fibrillation measurement using ring-shaped closed circuit microelectrode with lined-up cardiomyocyte cell network. J Nanobiotechnology. 2011;9:39 pubmed publisher

García Quiroz J, Camacho J. Astemizole: an old anti-histamine as a new promising anti-cancer drug. Anticancer Agents Med Chem. 2011;11:307-14 pubmed

Nishimuta H, Sato K, Mizuki Y, Yabuki M, Komuro S. Species differences in intestinal metabolic activities of cytochrome P450 isoforms between cynomolgus monkeys and humans. Drug Metab Pharmacokinet. 2011;26:300-6 pubmed publisher

Borowiec A, Hague F, Gouilleux Gruart V, Lassoued K, Ouadid Ahidouch H. Regulation of IGF-1-dependent cyclin D1 and E expression by hEag1 channels in MCF-7 cells: the critical role of hEag1 channels in G1 phase progression. Biochim Biophys Acta. 2011;1813:723-30 pubmed publisher

Li F, Hsieh Y, Kang L, Sondey C, Lachowicz J, Korfmacher W. MALDI-tandem mass spectrometry imaging of astemizole and its primary metabolite in rat brain sections. Bioanalysis. 2009;1:299-307 pubmed publisher

Ghosal A, Lu X, Penner N, Gao L, Ramanathan R, Chowdhury S, et al. Identification of human liver cytochrome P450 enzymes involved in the metabolism of SCH 530348 (Vorapaxar), a potent oral thrombin protease-activated receptor 1 antagonist. Drug Metab Dispos. 2011;39:30-8 pubmed publisher

Shim W, Back H, Jung S, Kim J, Jang Y, Lee B, et al. An aqueous extract of Poncirus fructus activates the prokinetic activity of 5-HT receptor subtype 4 without hERG interaction. J Ethnopharmacol. 2010;132:328-33 pubmed publisher

Hsieh Y, Li F, Korfmacher W. Mapping pharmaceuticals in rat brain sections using MALDI imaging mass spectrometry. Methods Mol Biol. 2010;656:147-58 pubmed publisher

Tsutsui H, Higashijima S, Miyawaki A, Okamura Y. Visualizing voltage dynamics in zebrafish heart. J Physiol. 2010;588:2017-21 pubmed publisher

Lee E, Oh J, Park H, Kim D, Lee J, Kim C, et al. Simultaneous gene expression signature of heart and peripheral blood mononuclear cells in astemizole-treated rats. Arch Toxicol. 2010;84:609-18 pubmed publisher

Nilsson M, Danielsson C, Skold A, Johansson A, Blomgren B, Wilson J, et al. Improved methodology for identifying the teratogenic potential in early drug development of hERG channel blocking drugs. Reprod Toxicol. 2010;29:156-63 pubmed publisher

Margulis M, Sorota S, Chu I, Soares A, Priestley T, Nomeir A. Protein binding-dependent decreases in hERG channel blocker potency assessed by whole-cell voltage clamp in serum. J Cardiovasc Pharmacol. 2010;55:368-76 pubmed publisher

Rojo L, Alzate Morales J, Saavedra I, Davies P, Maccioni R. Selective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer's disease. J Alzheimers Dis. 2010;19:573-89 pubmed publisher

Phan H, Moeller M, Nahata M. Treatment of allergic rhinitis in infants and children: efficacy and safety of second-generation antihistamines and the leukotriene receptor antagonist montelukast. Drugs. 2009;69:2541-76 pubmed publisher

Sawayama A, Chen M, Kulanthaivel P, Kuo M, Hemmerle H, Arnold F. A panel of cytochrome P450 BM3 variants to produce drug metabolites and diversify lead compounds. Chemistry. 2009;15:11723-9 pubmed publisher

Vu K, Gelli A. Astemizole and an analogue promote fungicidal activity of fluconazole against Cryptococcus neoformans var. grubii and Cryptococcus gattii. Med Mycol. 2010;48:255-62 pubmed publisher

Wible B, Kuryshev Y, Smith S, Liu Z, Brown A. An ion channel library for drug discovery and safety screening on automated platforms. Assay Drug Dev Technol. 2008;6:765-80 pubmed publisher

Musonda C, Whitlock G, Witty M, Brun R, Kaiser M. Chloroquine-astemizole hybrids with potent in vitro and in vivo antiplasmodial activity. Bioorg Med Chem Lett. 2009;19:481-4 pubmed publisher

Rossignoli P, Rodrigues A, Tinti T, Pereira O, Ellinger F, Chies A. The possible involvement of hyperpolarizing mechanisms in histamine-induced relaxation of the rat portal vein. J Smooth Muscle Res. 2008;44:129-41 pubmed

Gutierrez Castrellon P, Ramirez Mayans J, López Pérez G. [Efficacy and safety of astemizole in the treatment of allergic rhinitis and urticaria: a systematic review with meta-analysis]. Rev Alerg Mex. 2005;52:113-26 pubmed

Heidemann S, Sarnaik A. Arrhythmias after astemizole overdose. Pediatr Emerg Care. 1996;12:102-4 pubmed

Burke T, Mutnick A. Ventricular fibrillation and anoxic encephalopathy secondary to astemizole overdose. Ann Pharmacother. 1993;27:239-41 pubmed

Janssens M. Astemizole. A nonsedating antihistamine with fast and sustained activity. Clin Rev Allergy. 1993;11:35-63 pubmed

Rao K, Adlakha A, Verma Ansil B, Meloy T, Stanton M. Torsades de pointes ventricular tachycardia associated with overdose of astemizole. Mayo Clin Proc. 1994;69:589-93 pubmed

Richards D, Brogden R, Heel R, Speight T, Avery G. Astemizole. A review of its pharmacodynamic properties and therapeutic efficacy. Drugs. 1984;28:38-61 pubmed

Krstenansky P, Cluxton R. Astemizole: a long-acting, nonsedating antihistamine. Drug Intell Clin Pharm. 1987;21:947-53 pubmed

Levron J, Gillardin J, Sabbah A. [Astemizole: its pharmacokinetics and pharmacologic properties]. Allerg Immunol (Paris). 1990;22:233-41 pubmed

Janssens M, Caers L. Onset of action of astemizole. Int J Clin Pharmacol Res. 1991;11:219-29 pubmed

Hedrick C, Abate M. Astemizole effects on skin testing. Ann Pharmacother. 1992;26:1388-9 pubmed